PharmaCyte Biotech, Inc. (PMCB)

Company Overview
Nuvilex is an innovative company which aims at ionitiating a paradigm shift, generating revenue at the same time as creating cancer and other cell related solutions to treat important human diseases, such as pancreatic cancer while retaining our connections to natural products. The present effort underway will give rise to dramatic advances in cancer therapy and benefit millions of people worldwid
read more

Watch the video to learn about the probability of PharmaCyte Biotech, Inc. (PMCB) Chart Signal as of Feb 10, 2016

Hotstocked Precision will calculate the probabilities of PharmaCyte Biotech, Inc. (PMCB)

Rating:
Size: 656KB
Version: 1.1
Platform: Win/Mac
Downloads: 800,000+
FREE DOWNLOAD

QUOTE

As of 09:27PM EST February 10, 2016
$ 0.0659   -0 (-3.37%)
Today's Open: 0.0677 Previous Close: 0.0682
Today's High: 0.07 Volume: 871,746
Today's Low: 0.0636 Avg Vol: 1,229,891
52 Week High: 0.2615 Bid (size): 0
52 Week Low: 0.0385 Ask (size): 0

COMPANY INFO

To see the headquarters in Google Street View &trade, drag this yellow guy: over to the red pointer:

Contact Information:

Business Address: Meadows Corporate Park I, 12510 Prosperity Boulevard, Silver Spring, MD 20904, United States
Mailing Address: -
Phone: 240-696-6859
Fax: -
Website: http//www.nuvilex.com

Company Details:

Symbol: PMCB
SIC: -
State location: MD
Sector: -
State of Inc: NV
Employees: 1
Type: -

Key executives:

Name Age Position
2016
Dr. Gerald W. Crabtree 2016 COO
Patricia Gruden 2016 Chairman of the Board of Directors and CFO
Robert F. Ryan 2016 President, CEO

Watch the video to learn about the probability of PharmaCyte Biotech, Inc. (PMCB) Chart Signal as of Feb 10, 2016

This free program will calculate the probabilities of PharmaCyte Biotech, Inc. (PMCB) stock chart

Rating: Platform: Win/Mac
Price: FREE Version: 1.1
Size: 656KB Downloads: 800,000+
FREE DOWNLOAD

LATEST ARTICLES

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Files Restated Reports, Drops January 21, 2016

This Tuesday Pharmacyte Biotech Inc (OTCMKTS:PMCB) put up the restated financial reports the company announced were coming earlier. Yesterday the ticker dropped some 7% down to $0.067 per share on daily volume that went back up in the millions. read more

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Is Up Once More January 15, 2016

Investors didn't really react well to Pharmacyte Biotech Inc (OTCMKTS:PMCB)'s latest 8-K – until company management gift-wrapped it in boastful terms and plastered it on the company's newsfeed that is. read more

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Regains Lost Ground January 6, 2016

After a nasty dip to fresh 52-week low at $0.0459, Pharmacyte Biotech Inc (OTCMKTS:PMCB) started regaining lost ground. The stock logged two consecutive strong sessions, closing up 22% and then up 37% yesterday, even though volume cooled off significant... read more

Pharmacyte Biotech Inc (OTCMKTS:PMCB) At 52-Week Low on Restatement News January 4, 2016

After closing flat on the penultimate day of 2015, Pharmacyte Biotech Inc (OTCMKTS:PMCB) ended the year with a pant and a wheeze rather than with a bang. The company's stock took a big blow and dropped 27% on the charts on its biggest daily volume for t... read more

LATEST STOCK PROMOTIONS

The Guide and PMCB Nov 30, 2015, 08:45

  Good morning!   Hope everyone had an enjoyable Thanksgiving weekend. Which sectors will be on fire in the weeks ahead? Is the small cap segment about to break out? The four themes in this week’s Guide include:   ⇒ See which sectors could produce the best returns, moderate returns, and which ones to avoid ⇒ Why small stocks are about to break out and are set to bust through the closing read more

Promoter: Goldman Small Cap Research Paying Party: UNKNOWN Max Profit: 21.93% Gain at close: Pending
Stock: pmcb Compensation: $22,000 Avg $ Volume for Period: UNKNOWN

Cancer Treatment Approval Odds and Timing Just Moved Much Higher Oct 26, 2015, 08:12

  Good morning!   Last week was an incredible week for PharmaCyte Biotech (OTC – PMCB), which prompted us to issue a new research update. Major industry and company news released last week should take investor sentiment and the stock to a new level regarding the potential and timing of FDA approval for PharmaCyte’s pancreatic cancer treatment for patients with locally advanced pancreatic cancer.    Pancreatic read more

Promoter: Goldman Small Cap Research Paying Party: UNKNOWN Max Profit: 21.93% Gain at close: Pending
Stock: pmcb Compensation: $22,000 Avg $ Volume for Period: UNKNOWN

OTCJ : PharmaCyte (PMCB): FDA Trials Imminent Designed and Imminent Oct 22, 2015, 08:57

   October 22, 2015 Volume XVIII, Issue 52   OTC Journal Newsletter   PharmaCyte (PMCB): Moving To FDA Trials Soon To Be Moving Up The Charts Most people don't quite get the distinction, but moving from Studies to Trials is a very big deal for a Biotech company. In fact, the move to formal Trials from Studies allows Wall Street to place a much higher value on a company's read more

Promoter: OTCJournal Paying Party: UNKNOWN Max Profit: 0.66% Gain at close: Pending
Stock: pmcb Compensation: $14,000 Avg $ Volume for Period: UNKNOWN

Nuvilex, Inc. (NVLX) MESSAGE BOARD

Post # Subject Re Name Date
1 YGE=UP because it repaid $110ml debt on... 0
2 Such a deep anewsr! GD&RVVF 0
3 I love these areltics. How many words can... 0
4 Well, I think the Fed has to do a lot... 0
5 I just love how optimistic Jim Cramer and... 0
6 Dear Minamar,Can you give me some more... 0
7 Well mamiadcaa nuts, how about that. 0
8 I hope so 0
9 I'm a Dollarniare now! The scams on otc... 0
10 yes we are ging to be millionaires but it... 1
11 chemo kills weed does not 0
12 What happened to this stock today? It's... 0
13 Oh what happened? 2
14 Tanking like a ROCK!! Alpha Articles out!!! 4
15 FDA possible approval response to NVLX... 1
16 Yes it can 0
17 Man! I'd personally write some options... 0
18 20 Ducats? You jest my dear buffoon! 0
19 Oh Sheeheeheeheet! NVLX is fo' real ?... 0
20 50:1 split? Ha ha 0